Induction of the Formyl Peptide Receptor 2 in Microglia by IFN-␥ and Synergy with CD40 Ligand

A lzheimer's disease (AD)
4 is a progressive neurodegenerative disease that affects ϳ30 million individuals worldwide (1) . A hallmark of AD is the presence of senile plaques characterized by the deposition of aberrantly produced amyloid peptides (A␤), in particular the 42-aa form A␤ 42 , in association with neuronal damage (1) (2) (3) (4) . In addition to its direct neurotoxicity (5) , A␤ 42 is a potent activator of microglia, the mononuclear phagocytes in the brain that surround and infiltrate senile plaques composed of A␤ deposits and neurofibrillary tangles in AD (6, 7) . In vitro, A␤ 42 induces the chemotaxis and release of neurotoxins by mouse microglial cells activated by proinflammatory stimulants (8, 9) through the mouse formyl peptide receptor 2 (mFPR2), a seven-transmembrane, G protein-coupled receptor. The human homologue of mFPR2, formyl peptide receptor-like 1 (FPRL1), was originally identified as a low-affinity receptor for the bacterial chemotactic peptide formyl-methionylleucyl-phenylalanine (fMLF) (10) . FPRL1 also contributes to the internalization of A␤ 42 into the cytoplasmic compartment of macrophages where A␤ 42 forms fibrillary aggregates (11, 12) . Interestingly, in mouse microglia the expression of the FPRL1 counterpart mFPR2 was markedly enhanced when the cells were activated by ligands for TLRs such as LPS (a ligand for TLR4), CpG (a ligand for TLR9), PGN (a ligand for TLR2), and the proinflammatory cytokine TNF-␣ (13) (14) (15) (16) . Thus, the expression of mFPR2 in microglial cells is subject to up-regulation by both pathogen-and host-derived molecules associated with inflammatory responses.
IFN-␥ is a pleiotropic cytokine involved in the regulation of nearly all phases of immune and inflammatory responses, including the activation, growth, and differentiation of T cells, B cells, macrophages, NK cells, and other cell types such as endothelial cells and fibroblasts. In microglial cells, IFN-␥ induces changes in the expression level of at least 450 genes encoding chemokines, signaling molecules, and the MHC (17) . IFN-␥ also increases microglial responses to A␤ peptides by the production of proinflammatory and neurotoxic mediators (18) . Although under physiological conditions IFN-␥ remains low or absent in brain parenchyma, in inflammatory and immunological disease states of the CNS, IFN-␥ is significantly elevated presumably because of production by infiltrating T lymphocytes and NK cells (19) . Moreover, nonimmune cells of the CNS such as astroglia and neuronal cells have also been reported as potential sources of IFN-␥ (20 -22) . In a transgenic mouse model, overexpression of IFN-␥ in the hippocampus markedly increased the reactivity of microglial cells and their production of proinflammatory cytokines (23) . The production of IFN-␥ and other proinflammatory cytokines is particularly high in old age (24, 25) . In addition, in aged human and rodent brains the level of constitutively produced IFN-␥ is significantly higher than in the younger counterparts (26) . Therefore, IFN-␥ is not only a potent activator of microglial cells and plays an important role in inflammatory CNS diseases but also is also considered a risk factor for AD (27) .
To further elucidate the role of IFN-␥ in CNS inflammation and immune responses, in this study we investigated the capacity of this Th1 cytokine to regulate the expression and function of mFPR2 in microglia. We report that microglial cells stimulated with IFN-␥ expressed high levels of mFPR2 and migrate in response to a variety of mFPR2 agonist peptides including A␤ 42 . We additionally observed that IFN-␥ treatment enhanced the capacity of microglial cells to uptake A␤ 42 through mFPR2. Furthermore, IFN-␥ up-regulated the expression of CD40 on the microglial cell surface, and soluble CD40 ligand (CD40L) markedly increased the effect of IFN-␥ on the expression of mFPR2. Our study suggests that IFN-␥ and CD40 may profoundly affect microglial cell responses in the pathogenic process of proinflammatory CNS diseases in which mFPR2 agonist peptides are elevated.
Materials and Methods
Reagents and cells
Recombinant murine IFN-␥ and recombinant murine soluble (s) CD40L were purchased from PeproTech. A neutralizing anti-TNF-␣ Ab and isotype Ab rat IgG I were purchased from Endogen. fMLF and LPS were purchased from Sigma-Aldrich. SB202190, PD098059, and BAY117082 were obtained from Calbiochem. The A␤ 42 peptide was from California Peptide Research. Abs specific for total ERK1/2, ERK1/2 phosphorylated (p-) at Tyr 204 (p-ERK), total p38 MAPK, p-p38 MAPK, total IB-␣ and p-IB-␣, total Akt, and Akt phosphorylated at Ser 473 (p-Akt) were purchased from Cell Signaling Technology. The murine microglial cell line N9 was a gift from Dr. P. Ricciardi-Castagnoli (Universita Degli Studi di Milano-Bicocca, Milan, Italy) and was grown in IMDM supplemented with 5% heat-inactivated FCS, 2 mM glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 50 M 2-ME. Primary murine microglial cells were isolated from 1-day-old newborn C57BL/6 mice and grown in DMEM supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 g/ml streptomycin, 1 M HEPES, 2.5 g/ml Fungizone, 100 M nonessential amino acids, and 5 g/ml insulin. N9 cells grown to 4.0 ϫ 10 6 cells per 25-cm 2 flask were used for experiments except for Western immunoblotting, in which 1 ϫ 10 6 cells/well cultured on 6-well plates were used. Primary microglial cells isolated from newborn mice were cultured at 1.0 ϫ 10 6 cells/ml in 5-ml polypropylene round-bottom tubes (BD Labware) for experiments.
Chemotaxis assays
Chemotaxis assays for microglial cells were performed with 48-well chemotaxis chambers and polycarbonate filters (8-m pore size) (NeuroProbe) as described (15, 28) . The results are expressed as the mean Ϯ SD of the chemotaxis index (CI), which represents the fold increase in the number of migrated cells counted in three high-power fields (ϫ400) in response to chemoattractants over spontaneous cell migration (to control medium).
RT-PCR
Total RNA was extracted from cells with a RNeasy mini kit and depleted of contaminating DNA with RNase-free DNase (Qiagen). For amplification of the mFPR2 gene, primers 5Ј-TCTACCATCTCCAGAGTTCTGTTG G-3Ј (sense) and 5Ј-TACATCTACCACAATGTGAACTA-3Ј (antisense) were designed to yield a 268-bp product. Mouse ␤-actin primers were TGTGATGGTGGGAATGGGTCA (sense) and TTTGATGTGACGCACG ATTTCCC (antisense), which yield a product of 514 bp. Mouse CD40 primers were CGCTATGGGGCTGCTTGTTGACAG (sense) and GACG GTATCAGTGGTCTCAGTGGC (antisense), which yield a product of 400 bp. RT-PCR was performed with 0.5 g of total RNA for each sample (High Fidelity ProSTAR HF system; Stratagene), consisting of a 15-min reverse transcription at 37°C, 1 min inactivation of Moloney murine leukemia virus reverse transcriptase at 95°C, 40 cycles of denaturing at 95°C (45 s), annealing at 55°C (45 s), and extension at 72°C (1 min) with a final extension for 10 min at 72°C. All PCR products were resolved by 1.5% agarose gel electrophoresis and visualized with ethidium bromide. For quantitation, gels were scanned and the pixel intensity for each band was determined using the ImageJ program (NIH Image) and normalized to the amount of ␤-actin.
Fluorescence confocal microscopy
N9 cells were seeded at 2.8 ϫ 10 4 cells/well on eight-well chamber slides (Nalge Nunc International) for 24 h. The cells were then treated at 37°C with IFN-␥ or CD40L or both in combination for 12 h. Activated N9 cells were further treated in the presence or absence of G protein receptor deactivator pertussis toxin (PTX) for 1 h followed by A␤ 42 (50 g/ml) for 30 min. The cells were fixed in 2% paraformaldehyde for 20 min at room temperature, washed with PBS, and incubated with 5% normal goat serum (Sigma-Aldrich) in PBS plus 0.05% Tween 20 for 1 h to reduce nonspecific binding of Abs to the cell surface and for cell permeabilization. An anti-A␤ 42 Ab (Sigma-Aldrich) was applied to the slides, which were further incubated for 1 h at room temperature. After three rinses with PBS, the slides were incubated with FITC-conjugated goat anti-mouse IgG (BD Pharmingen) in TBS containing 1% BSA for 60 min. After three washes with PBS, the slides were stained with propidium iodide (PI) for 20 min at room temperature. The slides were mounted with an anti-fade, water-based mounting medium and analyzed under a laser-scanning confocal fluorescence microscope (Zeiss LSM510 NLO Meta). Excitation wavelengths of 488 nm (for FITC) and 561 nm (for PI) were used to generate fluorescence emission in green (for A␤ 42 ) and red (for nuclei), respectively. The intensity of green fluorescence detected for A␤ 42 was analyzed with ImageJ (NIH software).
Flow cytometry
N9 cells or primary mouse microglial cells stimulated with IFN-␥ alone or in combination with CD40L were examined for the expression of CD40 by labeling with PE-conjugated mAbs (BD Pharmingen). All staining procedures were completed at 4°C in Dulbecco's PBS containing 5 mM EDTA and 1% FCS. After extensive washing, the cells were analyzed using a FACScan flow cytometer (BD Biosciences).
Western immunoblotting
N9 cells grown to 1 ϫ 10 6 cells/well in 6-well plates were cultured overnight in FCS-free medium and stimulated with 10 ng/ml IFN-␥ and 1 g/ml CD40L each or in combination. LPS (300 ng/ml) was used as a positive control. The cells were lysed with 1 ϫ SDS sample buffer (62.5 mM Tris-HCI (pH 6.8), 2% SDS, 10% glycerol, and 50 mM DTT), sonicated for 15 s, and then heated at 100°C for 5 min. The cell lysate was 6 cells/ml) were stimulated with 10 ng/ml IFN-␥ for 24 h and the mRNA was examined for mRNA of mFPR2. The RT-PCR products were electrophoresed on a 1.5% agarose gel and visualized with ethidium bromide staining. The density of product bands was measured by ImageJ (NIH software) with normalization against ␤-actin bands. ‫,ء‬ Significantly increased cell migration (p Ͻ 0.05) as compared with medium control.
centrifuged at 12,000 rpm (4°C) for 5 min, and the protein concentration of the supernatant was measured by the Micro BCA protein assay system (Pierce). Proteins (50 g for each sample) were resolved by 10% SDS-PAGE (Invitrogen Life Technologies) and transferred onto nitrocellulose membranes (Bio-Rad). The membranes were blocked for 2 h at room temperature in 3% nonfat milk prepared in Tris-buffered saline-T (10 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.1% Tween 20) and probed with anti-p-p38, p-ERK1/2, p-IB-␣ Abs overnight at 4°C. The membranes were then washed and incubated with HRP-conjugated secondary Ab for 1 h at room temperature. The proteins were visualized using a SuperSignal chemiluminescent substrate (Pierce) and BIOMAX-MR film (Eastman Kodak). For detection of total p38, ERK1/2, and IB-␣, the membranes were stripped with Restore Western blot stripping buffer (Pierce) followed by incubation with specific Abs.
Statistical analysis
All experiments were performed at least three times. The statistical significance of the differences in the mean values (ϮSD) between test and control groups was analyzed with a two-tailed t test. All mean values (ϮSD) were obtained from at least three experiments. p values equal to or Ͻ0.05 were considered statistically significant.
Results
IFN-␥ induces the expression of functional mFPR2 in microglia
The mouse microglial cell line N9 and primary microglial cells treated with IFN-␥ increased their expression of mFPR2 mRNA. The effect of IFN-␥ was concentration and time dependent (Fig. 1,  A and B) , with optimal induction of mFPR2 at 10 ng/ml for 12 h. Although nonstimulated primary microglial cells isolated from the brains of newborn mice expressed a relatively higher baseline level of mFPR2 mRNA as compared with nonstimulated N9 cells (13) , this was probably due to a higher level of activation or differentiation status of the primary cells. Nevertheless, IFN-␥ treatment also significantly enhanced the level of mFPR2 mRNA in these cells (Fig. 1C) . The increased mFPR2 mRNA expression in IFN-␥-stimulated N9 microglial cells was associated with cell chemotaxis in response to mFPR2 agonist peptides, including fMLF derived from Gram-negative bacteria and A␤ 42 associated with AD (Fig. 2, A and B) . Similar results were obtained with primary murine microglial cells (Fig. 2, C and D) .
To ascertain the purity of IFN-␥, we tested polymyxin B, an LPS inhibitor, and found that it did not affect the capacity of IFN-␥ to induce the expression of functional mFPR2 in microglial cells. In contrast, polymyxin B inhibited the effect of LPS on mFPR2 induction (Fig. 2E) . Thus, the capacity of IFN-␥ to induce mFPR2 in mouse microglial cells was not dependent on contaminating LPS.
Involvement of MAPK in the up-regulation of mFPR2 in microglial cells by IFN-␥
Because it has been reported that IFN-␥ activates MAPKs and NF-B in microglial cells (29, 30) , we assessed their role in IFN-␥ induction of mFPR2. Fig. 3 shows that the level of mFPR2 mRNA induced by IFN-␥ was significantly reduced in microglial cells when the cells were pretreated with SB202190, a p38 MAPK inhibitor, the MEK-ERK1/2 inhibitor PD98059, or the highly selective IB-␣ phosphorylation inhibitor BAY117082 (Fig. 3, A- 
C).
This was accompanied by attenuated cell migration in response to mFPR2 agonist (Fig. 3, D-F) . These results suggest that p38 and ERK1/2 MAPKs as well as NF-B are important mediators for IFN-␥ to induce the expression of functional mFPR2 in microglial cells. 
IFN-␥ and CD40L synergistically increase CD40 expression by microglia
Because IFN-␥ has been reported to increase the expression of CD40 by microglial cells, which, in turn, are further activated by CD40 to produce proinflammatory cytokines, we examined whether CD40 participates in the regulation of mFPR2. We found that, consistent with the previously published results (31-34), nonstimulated N9 microglial cells expressed low levels of CD40 mRNA and cell surface CD40 protein, but the expression was progressively increased after stimulation with IFN-␥ as well as CD40L. As shown in Fig. 4 , CD40 mRNA was rapidly up-regulated by IFN-␥ or CD40L alone at 3 h after stimulation (Fig. 4A) . The effect was pronounced when IFN-␥ and CD40L were used in combination. This was accompanied by an up-regulated cell surface expression of CD40 (Fig. 4B) . The effect of IFN-␥ alone was delayed and a significantly up-regulated cell surface CD40 was seen at 12 h (Fig. 4C) . These results suggest that although CD40L and IFN-␥ each enhances the expression of CD40 in microglial cells, their combination results in a more rapid up-regulation. In contrast, unlike CD40, the expression of CD14 in microglial cells was not changed by treatment with IFN-␥ or CD40L at the time points tested in this study (data not shown), indicating their preferential regulatory activity.
CD40L and IFN-␥ synergistically promote the expression and function of mFPR2 in microglial cells
We then examined the function of CD40 expressed by IFN-␥ stimulated microglial cells. Fig. 5A shows cross-linking of the low levels of CD40 on nonstimulated microglia by its soluble ligand (CD40L) did not induce the expression of mFPR2 mRNA, nor did CD40L treatment promote the chemotaxis responses of the cells to mFPR2 agonist peptides. However, CD40L markedly enhanced the expression of mFPR2 by microglial cells incubated with IFN-␥ for 6 h, when the effect of IFN-␥ on mFPR2 gene expression was at a low level (Fig. 5B) . The same results were observed in experiments with primary mouse microglial cells (Fig. 5C ). We also found that pretreatment of microglial cells with IFN-␥ for 2 h followed by CD40L for 4 h was sufficient to significantly enhance the expression of mFPR2 in microglial cells (Fig. 5D ), in association with increased cell chemotaxis (Fig. 5E ).
CD40L and IFN-␥ synergistically promote the uptake of A␤ 42 peptide by microglia through mFPR2
As our previous studies showed that microglial cells activated by TLR agonists increased their capacity to uptake A␤ 42 peptides via mFPR2 (14, 15), we therefore investigated whether cells treated by IFN-␥ in the presence or absence of CD40L also might increase A␤ 42 ingestion. Fig. 6 shows that N9 microglial cells treated with IFN-␥ alone increased their capacity to endocytose A␤ 42 peptide as measured by confocal microscopy (Fig. 6A) . In contrast, whereas CD40L alone slightly increased the levels of A␤ 42 fluorescence in microglial cells, its combination with IFN-␥ resulted in a markedly enhanced A␤ 42 localization in the cytoplasmic compartment of microglial cells as shown by significantly increased values of the fluorescence intensity (FI) for cell-associated A␤ 42 and increased percentage of A␤ 42 -positive cells (Fig. 6, B and C) .
The results were confirmed with primary microglial cells (Fig. 6 , D and E). The ingestion of A␤ 42 by microglial cells stimulated with IFN-␥ or in combination with CD40L was significantly inhibited by PTX, an inhibitor of G␣ i protein-coupled receptors, or by another mFPR2 agonist, W pep ( Fig. 6 and data not shown), suggesting that mFPR2 is involved in A␤ 42 uptake by microglia activated by IFN-␥ alone or in combination with CD40L. Interestingly, a slightly increased A␤ 42 uptake by microglial cells treated with CD40L alone was not inhibited by PTX, suggesting that CD40L may increase the expression of other putative A␤ 42 binding molecules that might weakly assist in cell uptake of A␤ 42 (35) .
Enhanced activation of MAPKs and IB-␣ in microglial cells stimulated by IFN-␥ and CD40L
To elucidate the mechanistic basis for the synergistic effect of CD40L and IFN-␥ on the induction of mFPR2 in microglial cells, we evaluated the activation of signaling pathways involving MAPKs and IB-␣, a key molecule controlling the activation of NF-B. In N9 cells treated with IFN-␥ alone, phosphorylation of p38 was detected at 1 h, whereas activated ERK1/2 and IB-␣ were detected at 6 h (Fig. 7A) . IFN-␥ did not induce detectable levels of phosphorylated JNK in microglial cells (data not shown).
In contrast, microglial cells treated with CD40L alone showed detectable phosphorylation of p38, ERK1/2, and IB at 1 h. Furthermore, microglial cells pretreated with IFN-␥ for 3 h followed by stimulation with CD40L showed a more rapid phosphorylation of p38, ERK1/2 (15 min), and IB-␣ (30 min) (Fig. 7B) . It is interesting to note a unique pattern of phosphorylated vs nonphosphorylated IB-␣ species in microglial cell stimulated by both IFN-␥ and CD40L, presumably caused by the rapid degradation and de novo synthesis of the IB-␣ species. These results indicate that IFN-␥ and CD40L synergistically activate important signaling molecules involved in promoting the expression of mFPR2 in microglial cells.
Involvement of TNF-␣ in the induction of mFPR2 by IFN-␥ and CD40L
Because IFN-␥ has been reported to induce TNF-␣ expression in a variety of cell types including microglia and, more importantly, since our previous study showed that TNF-␣ (18, 36 -38) is a potent inducer of mFPR2 in microglial cells (16), we assessed whether TNF-␣ is involved in the effect of IFN-␥ on mFPR2 expression. We found that a TNF-␣-neutralizing Ab reduced the level of mFPR2 expression in both a microglial cell line (29 Ϯ 4%) and in primary microglial cells (70 Ϯ 3%) stimulated by IFN-␥ (Fig. 8, A and B) . The anti-TNF-␣ Ab also partially inhibited the synergistic induction of mFPR2 by IFN-␥ in combination with CD40L (37 Ϯ 4%) (Fig. 8C) . These results confirmed the previously reported capacity of IFN-␥ to induce the production of TNF-␣ by microglial cells and indicate that TNF-␣ contributes to the induction of mFPR2 by IFN-␥ and its synergy with CD40L in microglial cells.
Discussion
In this study, we identified IFN-␥ as an inducer of functional mFPR2 in murine microglial cells. The effect of IFN-␥ is further increased by cross-linking CD40, which is up-regulated on the cell surface of IFN-␥-activated microglial cells. This is the first demonstration of the synergistic regulation by two host-derived factors of the G protein-coupled receptor mFPR2 in microglial cells. As a cells/well) were stimulated with 10 ng/ml IFN-␥ for different time periods (min). B, N9 cells were treated with 1 g/ml CD40L for different time periods (minutes), or CD40L (1 g/ml) for different time points (min) after the cells were pretreated with IFN-␥ (10 ng/ml) for 3 h. LPS (300 ng/ml, 60 min) was used as a positive control. Whole cell lysates were electrophoresed on a 10% SDS-polyacrylamide gel. Western immunoblotting was performed using Abs specific for the p-p38, p-ERK1/2, or p-IB-␣, respectively. The membranes were then stripped and reprobed with Abs against total p38, ERK or IB-␣ as protein loading controls. consequence, microglial cells exhibited markedly increased chemotaxis in response to mFPR2 agonist peptides and endocytosis of A␤ 42 , a principal pathogenic factor of AD.
Although IFN-␥ is a classical T and NK cell cytokine produced mainly in the peripheral tissues during inflammatory and immune responses, its immunoreactivity and gene expression have been detected in human sensory neurons in the CNS (22) . In addition, it has been reported that human glial cells and rat astrocytes have the capacity to produce IFN-␥ after stimulation with proinflammatory cytokines (20, 21, 37) . Alternatively, under proinflammatory and immunological conditions in the CNS, T lymphocytes, which are capable of crossing the blood-brain barrier (BBB), may become a major source of IFN-␥. In fact, multiple pathogenic factors are capable of disrupting the integrity of BBB, allowing for the entry of T cells to the brain parenchyma in response to locally produced chemoattractants, mainly chemokines produced by activated astrocytes and microglial cells (27, 39) . It is interesting to note that increased levels of IFN-␥ are detected in the hippocampus of aged rodents (26) as well as in the CNS of senior normal human subjects, who comprise the principal risk population that succumbs to neurodegenerative diseases, in particular AD (24, 27, 40) . Thus, under pathological conditions and the aging process, IFN-␥ is readily available in the CNS as an inducer of mFPR2, which mediates the chemotactic responses microglial cells to multiple microbial and host-derived chemotactic agonist peptides, including AD-associated A␤ 42 (5, 9, 41) .
In our study, a relatively weaker effect of IFN-␥ on the induction of mFPR2 in microglial cells at early stages (6 h) of incubation was markedly increased by the soluble ligand for CD40. In nonstimulated microglial cells, CD40L showed little activity on the expression of mFPR2, which may be attributable to the low level of expression of CD40 by such cells. In contrast, IFN-␥ enhanced surface expression of CD40 by microglial cells, which then became responsive to CD40L by further increasing mFPR2 at both mRNA and functional levels. Consequently, IFN-␥ and CD40L synergistically promoted the microglial cell chemotaxis to A␤ 42 peptides and their internalization via mFPR2.
The CD40/CD40L dyad mediates a broad spectrum of inflammatory and immune responses in diseases including AD (42) (43) (44) . In a coculture model of primary neurons and microglia, CD40 cross-linking by soluble CD40L or an anti-CD40 Ab potently promoted the neurotoxicity of microglial cells induced by A␤ via the production of proinflammatory mediators (45) . Interestingly, in this model, microglial cells were incubated in the presence of IFN-␥, suggesting its "priming" effect on cell responses to CD40L. This is in agreement with our present study in which CD40 only exhibited its activity on mFPR2 induction in microglial costimulated by IFN-␥. In addition to activated microglia, CD40 was also detected on microvasculature in the brain of AD patients (46) , suggesting that CD40 may play an important role in orchestrating inflammatory responses in CNS diseases. To support the biological relevance of CD40 in the CNS, CD40L has been detected immunocytochemically in astrocytes in the brains of aged human subjects and AD patients. Likewise, in the brains of mice carrying the mutant amyloid precursor protein and presenilin 1, transgenes that develop AD-like pathology, as well as in rat injury models (47, 48) , CD40L was expressed by "reactive" astrocytes. Therefore, under inflammatory conditions, astrocytes, in addition to the T lymphocytes potentially infiltrating brain parenchyma due to breached BBB, provide essential signals for activation of CD40, which is up-regulated on activated microglial cells.
Our findings that IFN-␥ alone induces mFPR2 in microglia and its synergism with CD40 cross-linking may have important pathophysiological significance in the disease process of AD. In the AD brain, microglia accumulate at plaque lesions containing high levels of A␤ 42 (5, 9) . Although microglial cells are believed to mediate the "indirect" neurotoxicity of A␤ peptides by secreting toxins, they may play an essential role in phagocytosing and processing A␤ peptides (14, 15, 49 -52) . In culture, microglia isolated from human AD brains migrate to aggregated A␤ peptides and are capable of removing A␤ deposits. Consistent with this, cultured rat microglia interact with A␤ peptides, which become localized on the cell surface as well as in phagosome-like intracellular vesicles (53) . In in vivo experiments, A␤ peptides injected into rat striatum are rapidly phagocytosed by microglia (50), followed by degradation and clearance (52) . In mouse AD models, immunization with A␤ peptides (54, 55) or with Abs against A␤ (56) resulted in the reduction of A␤ deposits, apparently mediated by activated microglia. Thus, microglial uptake of A␤ peptides may represent a host defense to eliminate undesirable irritants in the CNS. However, microglial ingestion of A␤ peptides may also present the dilemma of a "double-edged" sword in that, as a consequence of prolonged exposure, A␤ peptides taken by human mononuclear phagocytes formed fibrillary aggregates in the cytoplasmic compartment and increased the apoptotic death of the cells (11, 12, 15) . It is therefore possible that the capacity of microglial cells or brain macrophages to eliminate or to promote deposition of A␤ peptides may be determined by the A␤ peptide burden in the brain and the duration of cell exposure. In this context, a fine tuning of microglial cell responses in the inflammatory milieu of AD will be crucial for maximizing the beneficial host responses while minimizing the detrimental consequences that may favor the progression of the disease. Further studies are therefore warranted to more clearly elucidate the biological significance of IFN-␥ and CD40 synergy in microglial activation in CNS diseases to facilitate the development of more effective therapeutic agents for AD and other inflammatory CNS diseases.
